Announcements Trials
Browse Landscape

Phase

Phase 2 9Phase 3 3Phase 1/2 3Phase NA 2Phase EARLY_PHASE1 1

Status

Terminated 3

Sponsor Class

INDUSTRY 3

Study Type

Interventional 3

Sponsor

Cancer Type

CNS 3

Conditions

Glioblastoma 3Recurrence 1Neoplasms 1Brain Neoplasms 1

Interventions

Cyclophosphamide 143pembrolizumab 126Nivolumab 114Carboplatin 99Dexamethasone 93Rituximab 91Paclitaxel 87Gemcitabine 85Lenalidomide 75Cytarabine 74Radiotherapy 72Cisplatin 70Bevacizumab 64Etoposide 62fludarabine phosphate 58fludarabine 56Docetaxel 54Bortezomib 54Ipilimumab 53Prednisone 49Doxorubicin 48Temozolomide 47Everolimus 46Erlotinib Hydrochloride 46Fluorouracil 44Azacitidine 44Capecitabine 43Calcium Dobesilate 43Filgrastim 42Melphalan 41

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 1/2 × Has results × Lomustine × Clear all
NCT04421378 2024-12-16

A Study of Selinexor in Combination With Standard of Care Therapy for Newly Diagnosed or Recurrent Glioblastoma

Karyopharm Therapeutics Inc

Phase 1/2 Terminated
74 enrolled 23 charts
CNS

Glioblastoma

NCT02765165 2021-07-23

Phase 1/2 Study of USL311 +/- Lomustine in Advanced Solid Tumors or Relapsed/Recurrent Glioblastoma Multiforme (GBM)

Proximagen, LLC

Phase 1/2 Terminated
26 enrolled 20 charts
CNS

Brain Neoplasms, Glioblastoma, Neoplasms, Recurrence

NCT00948389 2012-08-31

Study of CCNU (Lomustine) Plus Dasatinib in Recurrent Glioblastoma (GBM)

Bristol-Myers Squibb

Phase 1/2 Terminated
28 enrolled 16 charts
CNS

Glioblastoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡